CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
过继 T 细胞免疫治疗的表观遗传增强
英文原题：Epigenetic enhancement of adoptive T cell immunotherapy.
查看英文原题
Epigenetic enhancement of adoptive T cell immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Isshiki等人和Porazzi等人报道，抑制zeste同源物增强子1（EZH1）和EZH2通过重编程肿瘤使其更具免疫原性并改善T细胞表型，增强基于嵌合抗原受体（CAR）/T细胞受体（TCR）的疗法，并在血液肿瘤和实体瘤的临床前模型中证明了该联合方案的疗效。目前正在进行临床试验以评估其安全性和治疗潜力。
展开英文摘要原文
Isshiki et al. and Porazzi et al. report that inhibiting enhancer of zeste homolog 1 (EZH1) and EZH2 enhances chimeric antigen receptor (CAR)/T cell receptor (TCR)-based therapies by reprogramming tumors to be more immunogenic and improving T cell phenotype and demonstrate the efficacy of this combination in preclinical models across hematologic and solid cancers. Clinical trials are ongoing to evaluate its safety and therapeutic potential.
论文信息
- 作者
- Dai Z、Smith M
- 第一作者单位
- Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.United States
- 通讯作者单位
- Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: melodysm@stanford.edu.United States
- 期刊
- Cancer cell2025 Mar 10
- 原文标识
- PubMed 40068593 · DOI 10.1016/j.ccell.2025.02.022